Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway
刊名:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
出版年:2017
出版时间:February 2017
年:2017
卷:1863
期:2
页码:450-461
全文大小:1336 K
卷排序:1863
文摘
Identification of a novel Epo/HCK/PI3K/GATA-1 pathway HCK might be crucial for protection against ineffective erythropoiesis HCK is upregulated in hematopoietic stem cells cells from MDS and AML patients HCK is a probable pro-oncogene of MDS and AML with critical role in leukemogenesis HCK specific inhibitor increased leukemic cells death without affect normal hematopoietic stem cells HCK specific inhibitor represents a potential target for gene therapy